GU Cancers 2021 | PI3K/Akt pathway aberrations in mCRPC
Arun Azad, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, talks on plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts. Dr Azad discusses the emergence of circulating tumor DNA (ctDNA) as a source of molecular profiling and outlines the significance and implications of PTEN loss. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Dr Arun Azad, MBBS, PhD, FRACP, has participated in speaker bureaus with Astellas, Janssen, Novartis, Amgen, Ipsen, Bristol Myers Squibb, Merck Serono and Bayer, has received honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Pfizer, Amgen, Noxopharm and Merck Sharpe Dome; has participated in scientific advisory boards with Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, Merck Sharpe Dome, Amgen and Noxopharm; has received reimbursement for travel and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar and Pfizer; and has received research funding from Astellas (investigator), Merck Serono (investigator), Astra Zeneca (investigator), Bristol Myers Squibb (institutional), Astra Zeneca (institutional), Aptevo Therapeutics (institutional), Glaxo Smith Kline (institutional), Pfizer (institutional), MedImmune (institutional), Astellas (institutional), SYNthorx (institutional), Bionomics (institutional), Sanofi Aventis (institutional), Novartis (institutional) and Ipsen (institutional).
